News | October 11, 2021
Merck and Ridgeback seek EUA from U.S. FDA for molnupiravir
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
Ascletis is China's first biotech company which has obtained IND approvals of an oral RdRp inhibitor from both China NMPA and the U.S. FDA
Multiples is the first private equity (PE) investor in the company
They will commercialize molnupiravir in the international markets
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
Subscribe To Our Newsletter & Stay Updated
